ArticleInternational journal of chronic obstructive pulmonary disease2026
Diagnostic Value of miR-192-5p in the Progression of Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Heart Disease.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The development of chronic obstructive pulmonary disease (COPD) is often accompanied by pulmonary heart disease (PHD). However, PHD lacks effective diagnostic markers in its early stages, making it difficult to detect. miR-192-5p is closely associated with respiratory diseases and may serve as an effective diagnostic biomarker. This study aims to investigate the diagnostic value of miR-192-5p in PHD. Patients and Methods: This study included patients with COPD alone (n=120) and those with COPD complicated with PHD (n=140). Serum miR-192-5p levels were detected using RT-qPCR, while TNF-α and IL-6 concentrations were measured via ELISA kits. Hospitalization-related diagnostic indicators were concurrently collected for comparative analysis. The diagnostic value of miR-192-5p was assessed using receiver operating characteristic curve analysis, and risk factors were identified through logistic regression analysis. Results: miR-192-5p level is significantly downregulated in serum samples from non-PHD and PHD patients. It demonstrates diagnostic performance for PHD with an AUC of 0.789 (78.6% sensitivity, 64.2% specificity) and distinguishes healthy from non-PHD with an AUC of 0.873 (90.0% sensitivity, 70.0% specificity). And its low expression is one of the primary risk factors for PHD development. Further analysis reveals that miR-192-5p levels show a significant negative correlation with inflammatory markers and are closely associated with patients' cardiopulmonary function indicators. Conclusion: miR-192-5p is significantly downregulated in PHD, and low levels of miR-192-5p represent one of the risk factors for PHD development. It can effectively distinguish between healthy individuals and non-PHD patients, and demonstrating moderate diagnostic accuracy in distinguishing between non-PHD patients and PHD patients, and is expected to become a viable diagnostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.